Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'


News provided by

Research and Markets

03 Mar, 2015, 12:54 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Mar. 03, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/tvmk72/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering.

Continue Reading
This image opens in the lightbox
600769
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs.

SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.

The "Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Key Findings:

- Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years.
- As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan.
- In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
- In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia.
- Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.

Key Topics Covered:

Chapter 1: Introduction

Chapter 2: An Overview of Generic Drugs

Chapter 3: Regulatory Landscape

Chapter 4: Drug Class Availability & Leading Therapies

Chapter 5: Generic Drugs Industry Roadmap & Value Chain

Chapter 6: Key Market Players

Chapter 7: Market Analysis & Forecasts

Chapter 8: Conclusion & Strategic Recommendations

Companies Mentioned

  • ACETO Corporation
  • AMA (African Medicines Regulatory Agency)
  • AMRI (Albany Molecular Research, Inc.)
  • ASKA Pharmaceutical Company
  • AbbVie
  • Abbott Laboratories
  • Acino Holding
  • Actavis
  • Actelion
  • Adcock Ingram
  • Aesica Pharmaceuticals
  • Ajinomoto
  • Akron
  • Alexion Pharmaceuticals
  • Alfa Wasserman
  • Allergan
  • Almirall
  • Amgen
  • Amneal Pharmaceuticals
  • ApoPharma
  • Apotex
  • Arch Pharmalabs
  • Aspen Holdings
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Auxilium Pharmaceuticals
  • BD (Becton, Dickinson and Company)
  • BD Rx
  • BMS (Bristol-Myers Squibb)
  • BPI (Breckenridge Pharmaceutical Inc.)
  • Baxter BioScience
  • Baxter International
  • Bayer AG
  • Berlin Chemie
  • Biocon
  • Biogaran
  • Biogen Idec
  • Biogen Laboratorios
  • Boehringer Ingelheim
  • Boots UK
  • Breckenridge Pharmaceutical
  • CBER (Centre for Biologics Evaluation and Research)
  • CDER (Centre for Drug Evaluation and Research)
  • CDSCO (Central Drug Standards and Control Organization, India)
  • CFDA (China Food and Drug Administration)
  • Cadila Healthcare (Zydus Cadila)
  • Cadila Pharmaceuticals
  • Cedarburg Pharmaceuticals
  • Celgene Corporation
  • Celltrion Group
  • Chiesi Farmaceutici
  • Chugai Pharmaceutical Company
  • Cipla
  • Claris Injectables
  • Claris Lifesciences
  • Claris Otsuka
  • Coherus BioSciences
  • Consort Medical
  • Covidien
  • Cubist Pharmaceuticals
  • Cypress Pharmaceutical
  • Daiichi Sankyo
  • Daiichi Sankyo Espha
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Dusa Pharmaceuticals
  • EGA (European Generic Medicines Association)
  • EMA (European Medicines Agency)
  • ESTEVE Farma
  • ESTEVE Group
  • Egis Pharmaceuticals
  • Eisai Company
  • Eli Lilly and Company
  • Elmed Eisai Company
  • Endo International
  • Endo Pharmaceuticals
  • Eurofarma Laboratorios
  • FDA (Food and Drug Administration)
  • Ferring Pharmaceuticals
  • Forest Laboratories
  • Fresenius Kabi
  • Fuji Pharma Company
  • Fujifilm Corporation
  • Fujifilm Holdings Corporation
  • Fujifilm Pharma Company
  • GGL (Glenmark Generics Limited)
  • GSK (GlaxoSmithKline)
  • Galderma
  • Galenika
  • Gedeon Richter
  • Gedeon Richter PregLem
  • Genepharm
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Global Pharmaceuticals
  • Globalpharma
  • Grifols
  • Gruenenthal Group
  • Guangdong BeiKang Pharmaceutical Company
  • Hanmi Pharmaceutical Company
  • Health Canada
  • Hetero Drugs
  • Hi-Tech Pharmacal
  • Hikma Pharmaceuticals
  • Hospira
  • Impax Laboratories
  • Impax Pharmaceuticals
  • Ipsen
  • JHP Group Holdings
  • JHP Pharmaceuticals
  • JT (Japan Tobacco)
  • Janssen Pharmaceutica
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Kaken Pharmaceutical Company
  • Kaneka Corporation
  • Kowa Company
  • Kowa Health Care America
  • Kowa Pharmaceuticals America
  • Kowa Research Institute
  • Kremers Urban Pharmaceuticals
  • Krka (Krka, d. d.)
  • Kyowa Hakko Kirin Company
  • Kyowa Pharmaceutical Industry Company
  • Laboratorios Roemmers
  • Leo Pharma
  • Les Laboratoires Servier
  • Lil Therapeutics
  • Lundbeck (H. Lundbeck A/S)
  • Lupin
  • MN (Mustafa Nevzat) Pharma
  • Mallinckrodt
  • Maruho Company
  • Matrix Laboratories
  • Meda
  • Medley Farma
  • Meiji Holdings
  • Meiji Seika Pharma Company
  • Menarini Group
  • Merck KGaA
  • Merck Serono
  • Merck and Co.
  • Merz Pharma
  • Ministry of Health, Labour and Welfare (Japan)
  • Mitsubishi Chemical Holdings Corporation
  • Mitsubishi Tanabe Pharma
  • Mitsui & Company
  • Mitsui Group
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Company
  • Nippon Kayaku
  • Nippon Shinyaku
  • Nipro Pharma Corporation
  • Novartis International
  • Novo Nordisk
  • OLIC (Thailand)
  • Ono Pharmaceutical Company
  • Orion Corporation
  • Osaka Synthetic Chemical Laboratories
  • Otsuka Holdings Company
  • Otsuka Pharmaceutical Company
  • Paladin Labs
  • Par Pharmaceutical Companies
  • Pensa Dose
  • Pensa Pharm
  • Perrigo Company
  • Pfizer
  • Pharma Dynamics
  • Pharmstandard
  • Pierre Fabre (Laboratoires Pierre Fabre)
  • Piramal Enterprises
  • Piramal Group
  • Pliva (Pliva d.d.)
  • Prasco Laboratories
  • PregLem
  • Purdue Pharma
  • Qualitest and Vintage Pharmaceuticals
  • Ranbaxy Laboratories
  • Recordati
  • Regeneron Pharmaceuticals
  • Rising Pharmaceuticals
  • Roche Holding (F. Hoffmann-La Roche)
  • Roxane Laboratories
  • STADA Arzneimittel
  • Salix Pharmaceuticals
  • Samsung BioLogics
  • Samsung Bioepis
  • Samsung Group
  • Sandoz International
  • Sanofi
  • Sanofi-Aventis Nichi-Iko K.K.
  • Santen Pharmaceutical Company
  • Sawai Pharmaceutical Company
  • Seikagaku Corporation
  • Sequent Scientific
  • Servier Group
  • Shionogi & Company
  • Shire
  • Sigma-Tau
  • Somar (Grupo Farmaceutico Somar)
  • Strativa Pharmaceuticals
  • Strides Arcolab
  • Sumitomo Dainippon Pharma Company
  • Sun Pharmaceutical Industries
  • Supera Farma Laboratorios
  • Taisho Pharmaceutical Company
  • Taisho Pharmaceutical Holdings Company
  • Taisho Pharmaceutical Industries
  • Taiyo Pharmaceutical Industry Company
  • Takeda Pharmaceutical Company
  • Tanabe Seiyaku Hanbai Company
  • Taro Pharmaceutical Industries
  • Teijin
  • Teijin Pharma
  • Teva Pharmaceutical Industries
  • Teva-Kowa Pharma Company
  • The Medicines Company
  • Torrent Group
  • Torrent Pharmaceuticals
  • Towa Pharmaceutical Company
  • UCB
  • United Therapeutics Corporation
  • Valeant Pharmaceuticals International
  • Ventana Medical Systems
  • Vertex Pharmaceuticals
  • WHO (World Health Organization)
  • Warner-Chilcott
  • West-Ward Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/tvmk72/the_generic_drugs

Source: SNS Research

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.